Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study-Reference-Cited by-同舟云学术

Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study

Published:2016-11-28 Issue:7 Volume:123 Page:1115-1123
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sneige Nour¹,Hess Kenneth R.²,Multani Asha S.³,Gong Yun¹,Ibrahim Nuhad K.⁴

Affiliation:

1. Department of Pathology; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Department of Genetics; The University of Texas MD Anderson Cancer; Houston Texas

4. Department of Breast Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston Texas

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist.,2009

2. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer;Wolff;Arch Pathol Lab Med.,2007

3. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity;Hanna;Mod Pathol.,2014

4. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy;Tse;J Clin Oncol.,2011

5. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus;Troxell;Am J Clin Pathol.,2006

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular testing in breast cancer;Diagnostic Molecular Pathology;2024

2. Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites;Bulletin du Cancer;2023-12

3. HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?;Applied Immunohistochemistry & Molecular Morphology;2023-07-06

4. RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory;Modern Pathology;2021-10-18

5. Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer;Anticancer Research;2021-07-19